Pharmaceutical Pricing at the Change of Millennia

REFERENCES

• Grabowski H, Vernon J. A sensitivity analysis of expected profitability of pharmaceutical research and development. Manage Dec Econ 1992;3(1):36–40.
   Google Scholar
• Zelnio RN, Gagnon JP. The effects of price information on prescription drug product selection. Drug Intell Clin Pharm 1979;13:156–9.
   PubMedGoogle Scholar
• Chukkapalli R, Kolassa EM, Ogilvey S, Hayman-Taylor T. The 15 year trend in prices at launch for outpatient prescription medications. Unpublished.
   Google Scholar
• U.S. Senate. Special Committee on Aging. Prescription drug prices: are we getting our money's worth? Serial No. 101-F. Washington, DC, 1991
   Google Scholar
• Pryor D. A prescription for high drug prices. Health Aff 1990;9:101–9.
   Google Scholar
• Dranove D. Medicaid drug formulary restrictions. J Law Econ 198923:143–62.
   Google Scholar
• Curran JP. Strategic shifts in pricing policies. Pharm Exec 1986;6(Apr):92–4.
   Google Scholar
• Boston Consulting Group. The changing environment for U.S. pharmaceu-ticals. New York: Boston Consulting Group, April 1993.
   Google Scholar
• Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econ 1992;23:331–50.
   Google Scholar
• Bloom BS, Wierz DJ, Pauly MV. Cost and price of comparable branded and generic pharmaceuticals. JAMA 1986;256:2523–30.
   Google Scholar
• EMS America. National Prescription Audit. October-December 1994. Plymouth Meeting, PA: IMS America.
   Google Scholar
• Medispan Inc. Price Check-PC. December 1994. Indianapolis, IN: Medis-pan Inc.
   Google Scholar
• Pathak DS, Klinger PA. Predictive factors in bid purchasing of antibiotics. Top Hosp Pharm Manage 1981;1(1):17–28.
   Google Scholar
• Taylor S, Kucukarslan S, Sherrin T. Evidence and response to the impact of the Medicaid Drug Rebate Program (OBRA) on hospital pharmacy: a progress re-port from central Ohio. Hosp Pharm 1991;26:621–5.
   Google Scholar
• Palumbo FB, Schondelmeyer SW, Miller DW, Speedie SM. Battered bot-tom lines: the impact of eroding pharmaceutical discounts on health-care institu-tions. Am J Hosp Pharm 1992;49:1177–85.
   Google Scholar
• Wilensky GR, Blumberg LJ, Neumann PJ. Chapter 4. Pharmaceuticals and decision-making in the United States: cost consciousness and the changing locus of control. In: van Eimeren W, Horisberger B, eds. Socioeconomic evaluation of drug therapy. Berlin, New York: Springer-Verlag, 1988:32–45.
   Google Scholar
• Wertheimer Al, Grinner SK. Overview of international pharmacy pricing. PharmacoEconomics 1992;2:449–55.
   Google Scholar
• Anon. European price controls not sufficient to control drug spending without policies in place to control use. FDC Rep-Pinksheet 1994;(Jul 4):7–9.
   Google Scholar
• Brown RE, Luce BR. The value of pharmaceuticals: a study of selected conditions to measure the contribution of pharmaceuticals to health status. Wash-ington, DC: Battelle Medical Technology and Policy Research Center, March 1990.
   Google Scholar
• Andersson F, McMenamin P. International price comparisons of pharma-ceuticals—a review of methodological issues. London and Washington, DC: Bat-telle Medical Technology and Policy Centre (MEDTAP), 1992.
   Google Scholar
• U.S. General Accounting Office. Prescription drugs: companies typically charge more in the United States than in Canada. Report to the Chairman, House Subcommittee on Health and the Environment, Committee on Energy and Com-merce. GAO/HRD-920119. Washington, DC: September 1992.
   Google Scholar
• Soumerai SB, Ross-Degnan D. Experience of state drug benefit programs. Health Aff 1990;9:36–54.
   Google Scholar
• Goodman JC, Dolan EG. Economics of public policy. St. Paul, MN: West Publishing Company, 1985.
   Google Scholar
• Kozma CM, Reeder CE, Lingle EW. Expanding Medicaid drug formulary coverage: effects on utilization of related services. Med Care 1990;28:963–76.
   Google Scholar
• Reutzel Ti. The nature and consequences of policies intended to contain costs in outpatient drug insurance programs. Clin Ther 1993;15:752–64.
   Google Scholar
• Bloom BS, Jacobs J. Cost effects of restricting cost-effective therapy. Med Care 1985;23:872–80.
   Google Scholar
• Hefner DL. Cost effectiveness of a restrictive drug formulary. Washington, DC: National Pharmaceutical Council, 1980.
   Google Scholar
• Moore WI, Newman RI. U.S. Medicaid drug formularies: do they work? PharmacoEconornics 1992;1\(Suppl 1):28–31.
   Google Scholar
• Smith MC, Simmons S. A study of the effects of formulary limitations in Medicaid programs. Adrnin Policy J 1982;2:169–98.
   Google Scholar
• Rucker TD, Morse ML. The Medicaid drug program in Louisiana: critique of the Hefner-Pracon Study. Am J Hosp Pharm 1980;37:1350–3.
   Google Scholar
• Nelson AA, Reeder CE, Dickson WM. The effect of a Medicaid drug co-payment program on the utilization of prescription services. Med Care 1984;22:724–36.
   Google Scholar
• Soumerai SE, Avom I, Ross-Degnan D, Gortrnaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med 1987;317:550–6.
   Google Scholar